featured
Temsirolimus vs Sorafenib as Second-Line Therapy After Sunitinib in MRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol 2013 Dec 02;[EPub Ahead of Print], TE Hutson, B Escudier, E Esteban, GA Bjarnason, HY Lim, KB Pittman, P Senico, A Niethammer, DR Lu, S Hariharan, RJ MotzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.